Skip to main content

Day: December 4, 2025

Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)

APONVIE, an aprepitant product, highlighted as the only FDA-approved IV formulation Neurokinin-1 (“NK-1”) antagonist indicated for the prevention of PONV in adults, with a long half-life and quicker onset than oral aprepitantAprepitant alone, or added to a multimodal regimen, recognized as significantly reducing the risk of PONV, and aprepitant monotherapies are noted as more effective compared to 5-HT3 receptor antagonists for postoperative vomiting preventionPost-discharge nausea and vomiting (PDNV) recognized as a significant risk to discharged postoperative patients and the role of long-acting antiemetic strategies highlighted as extending protection beyond the recovery room and into the home settingCARY, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) — Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage...

Continue reading

Skycorp Solar Group Limited Announces $2 Million Share Repurchase Programme

Ningbo, China, Dec. 04, 2025 (GLOBE NEWSWIRE) — Skycorp Solar Group Limited (Nasdaq: PN) (the “Company”), a solar PV product provider engaged in the manufacture and sale of solar cables and solar connectors, today announced its board of directors has approved the adoption of a Share Repurchase Programme (the “Programme”), under which the Company plans to repurchase its ordinary shares for a maximum total consideration of up to US$2,000,000. The purpose of the Programme is to optimize the Company’s capital structure, enhance earnings per share, and create long-term value for shareholders. To date, the Company has repurchased an aggregate of 60,000 shares for a total consideration of US$51,972. The Programme has been and will continue to be funded from the Company’s own resources. The Company will provide periodic updates on the...

Continue reading

Volatus Aerospace Appoints Lieutenant-General (Ret’d) Christopher J. Coates to Board of Advisors

MONTREAL and TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) — Volatus Aerospace Inc. (TSXV:FLT) (OTCQB:TAKOF) (Frankfurt:A3DP5Y/ABB.F) (“Volatus” or “the Company”), a leader in aerial and defense solutions, is pleased to announce the appointment of Lieutenant-General (Ret’d) Christopher J. Coates, CMM, MSM, CD, LOM, to its Board of Advisors. His appointment strengthens the Company’s defense expertise as Volatus advances its vision to support the Canadian Armed Forces (CAF), NORAD modernization, and allied defense partners with Canadian-made uncrewed aerial systems (UAS), training, and operational capabilities. Lieutenant-General Coates is one of Canada’s most respected defense and security leaders, having served in senior positions across the Canadian Joint Operations Command (CJOC), North American Aerospace Defense...

Continue reading

Landstar System Announces Special Dividend

JACKSONVILLE, Fla., Dec. 04, 2025 (GLOBE NEWSWIRE) — Landstar System, Inc. (NASDAQ: LSTR), a technology-enabled, asset-light provider of integrated transportation management solutions delivering safe, specialized transportation logistics services, announced that on December 3, 2025, its Board of Directors declared a special one-time cash dividend in the amount of $2.00 per share, payable on January 21, 2026 to stockholders of record as of the close of business on January 6, 2026. “Landstar’s strong balance sheet and free cash flow generation position us to continue delivering value to our stockholders,” said Landstar President and Chief Executive Officer Frank Lonegro. The Company purchased a total of 1,281,863 shares of its common stock at an aggregate cost of approximately $180.9 million during the first 11 months of its 2025...

Continue reading

FuelCell Energy Announces Fourth Quarter and Fiscal Year 2025 Results Conference Call on December 18, 2025 at 10:00 A.M. Eastern Time

DANBURY, Conn., Dec. 04, 2025 (GLOBE NEWSWIRE) — FuelCell Energy, Inc. (Nasdaq: FCEL) – announced the upcoming release of its fourth quarter and fiscal year 2025 results prior to the Stock Market Open on Thursday, December 18, 2025. FuelCell Energy management will subsequently host a conference call with investors beginning at 10:00 a.m. Eastern Time the same day to discuss the results and provide a business update. Participants can access the live call via webcast on the Company website or by telephone as follows:The live webcast of this call and supporting slide presentation will be available at www.fuelcellenergy.com. To listen to the call, select ‘Investors’ on the home page, proceed to the ‘Events & Presentations’ page and then click on the ‘Webcast’ link under the December 18th earnings call event listed. Alternatively,...

Continue reading

ZenaTech Expands Drone as a Service to Australia with Offer to Acquire a Survey Firm Serving Government and Natural Resources and Commercial Sectors

VANCOUVER, British Columbia, Dec. 04, 2025 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology business solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, today announces it has signed an offer to acquire a long-established, multi-office Queensland, Australia-based surveying and spatial services firm, marking a significant step in the company’s global expansion strategy. This targeted acquisition represents ZenaTech’s first entry into Australia and provides a strategic gateway for expanding the Drone as a Service platform throughout the broader Asia-Pacific (APAC) region, strengthening the company’s position in one of the world’s most active mining and industrial ecosystems. “Australia...

Continue reading

America’s Car-Mart Reports Second Quarter Fiscal Year 2026 Results

ROGERS, Ark., Dec. 04, 2025 (GLOBE NEWSWIRE) — America’s Car-Mart, Inc. (NASDAQ: CRMT) (“we,” “Car-Mart” or the “Company”), today reported financial results for the second quarter ended October 31, 2025.Second Quarter Key Highlights (FY’26 Q2 vs. FY’25 Q2, unless otherwise noted)Closed $300.0 million term loan and repaid revolving line of credit balance, enhancing capital structure and expanding flexibility to support originations and operations Total cash, including restricted cash, increased to $251.0 million from $124.5 million at the start of the fiscal year Interest expense decreased 13.1%, reflecting improvements to the securitization platform and a more favorable interest rate environment Credit applications were up 14.6% Accounts over 30 days past due improved 36 basis points year-over-year, and 62 basis points sequentially...

Continue reading

Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting

Cohort 1 data from multiple dose ReSPECT- Leptomeningeal Metastases (LM) trial showed no dosage limiting toxicity ReSPECT-Glioblastoma (GBM) trial of REYOBIQ as a novel therapeutic for recurrent GBM demonstrated promising safety and efficacy signal, supporting continued Phase 2 enrollment and investigation MRI combined with SPECT imaging biomarkers effectively evaluate overall survival response with REYOBIQ in recurrent GBM treatment and help guide personalized patient planning HOUSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces three positive clinical data update presentations at the World Federation of Neuro-Oncology...

Continue reading

Nayax Announces Acquisition of Lynkwell

Acquisition enhances Nayax’s solution in the EV charging ecosystem with an integrated platform combining advanced software and payment solutions. HERZLIYA, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) — Nayax Ltd. (Nasdaq: NYAX; TASE: NYAX), a global commerce enablement and payments platform designed to help merchants scale their business by simplifying payments and maximizing loyalty, today announced the acquisition of Lynkwell, an AI-enabled EV Charging platform. The acquisition reinforces Nayax’s strategy to deliver a comprehensive platform that unites payment acceptance with advanced operational management software across the verticals it serves. In EV charging, Nayax has expanded through partnerships that embed its payment technology into a range of EV charging equipment, and Lynkwell extends that strategy with a powerful, purpose-built...

Continue reading

MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress

Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026 Topline results from Phase 2 VISTA trial of ML-007C-MA for Alzheimer’s disease psychosis expected in the second half of 2027 Raised $296.5 million in gross proceeds from initial public offering and concurrent private placement completed in October 2025 Cash, cash equivalents and short-term investments sufficient to fund operations through 2027SAN FRANCISCO and BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) — MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today reported financial results for the third quarter of 2025 and highlighted recent progress and upcoming milestones. “2025 was...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.